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AMPK is a physiological cellular energy sensor 
that is activated by phosphorylation at Thr172 in 
response to changes in cellular ATP levels. AMPK has 
been recognized as an important upstream signaling 
intermediate intimately involved in the regulation of the 
mTOR pathway [1]. AMPK responds to energy stress 
by suppressing cell growth and biosynthetic processes, 
in part through its inhibition of the rapamycin-sensitive 
mTOR (mTORC1) pathway. In addition, AMPK directly 
phosphorylates the mTOR binding partner raptor on two 
well-conserved serine residues, and this phosphorylation 
induces 14-3-3 binding to raptor. The phosphorylation 
of raptor by AMPK is required for the inhibition of 
mTORC1 and cell cycle arrest induced by energy 
stress. Recent studies show that raptor was identified as 
a direct substrate of the AMPK. AMPK phosphorylates 
raptor on Ser722/Ser792 which it is essential for inhibition 
of the raptor-containing mTOR complex I (mTORCI). 
Moreover, AMPK is activated by the adenosine analogue, 
5-aminoimidazole-4-carboxamide (AICA)-riboside 
(AICAR) and metformin. These drugs have been used 
to inhibit the growth and survival of breast cancer and 
glioblastomas cells [2].
mTOR is a large protein kinase with two different 
complexes. One complex contains mTOR, GβL and raptor, 
which is a target of rapamycin [3]. The other complex, 
insensitive to rapamycin, includes mTOR, GβL, Sin1, and 
rictor. The mTOR-rictor complex phosphorylates Ser473 of 
Akt/PKB, which is essential for full Akt/PKB activation. 
We have evidence in TSC-deficient proximal tubular cells 
accumulates  significant  amounts  of  ROS  compared  to 
wild type cells (data not shown). Accumulation of ROS 
is associated with activation/phosphorylation of Akt at 
Ser473, inactivation/phosphorylation of tuberin at Thr1462 
and activation mTOR/rictor complex II [3]. In addition, 
Akt can be activated through the feedback mechanism 
of mTOR-rictor complex activation. Additional evidence 
indicates that rictor is phosphorylated at Thr1135 by 
p70S6K, which negatively regulates mTORC2 protein 
complex as part of a negative feedback mechanism 
controlling Akt activity [4].
Targeting mTOR is emerging as an important 
approach in cancer therapeutics [3]. Early clinical trials 
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Figure 1: Rapamycin blocks ROS generation and directly or/and indirectly activates AMPK. Activation of AMPK by 
rapamycin may impact directly on OGG1 activation or indirectly through blocking the activity of mTOR.Oncotarget 2011; 2:  958 - 959 959 www.impactjournals.com/oncotarget
show that tuberous sclerosis complex (TSC) and Van 
Hippel-Lindau  (VHL)-related  kidney  tumors  regress  in 
response to treatment with the mTOR inhibitor, rapamycin 
[5]. Treatment of TSC patients with rapamycin resulted 
in reduction in angiomyolipoma volume by nearly 50% 
[5]. mTOR serves a critical role in the regulation of the 
translational machinery and, in doing so, affects cellular 
responses to growth, proliferation, and differentiation, all 
of which are abnormally manifested in TSC lesions. TSC 
inhibits Rheb-GTP by promoting conversion to Rheb-
GDP to block mTOR activity [6]. Although rapamycin 
can effectively inhibit mTOR activity and decrease 
kidney tumor size, the mechanisms involved are not fully 
understood On the other hand, a deficiency in DNA repair 
can lead to accumulated multiple gene mutations and result 
in tumors development [7]. Many of these mutations can 
occur as a result of irreparable or incompletely repaired 
genomic DNA, due to deficiencies in DNA repair enzymes 
such as 8-oxoG-DNA glycosylase (OGG1). Loss of OGG1 
has major consequences in multistep carcinogenesis in the 
kidney and other organs [7]. Decreased OGG1 expression 
and activity leads to a mutator phenotype, with faulty 
repair of oxidized DNA lesions, and an accumulation of 
the oxidized DNA product (8-oxodG).
Upregulation of OGG1 was detected in several cancer 
cells treated with AMPK activator, AICAR [8]. Activation 
of AMPK resulted in activation/phosphorylation of TSC 
at Thr1387 and suppressed the mTOR activity. Moreover, 
rapamycin treatment led to a robust phosphorylation and 
activation of AMPK and ACC to a degree similar to that 
observed with AICAR stimulation in TSC2+/− treated with 
HG further supporting the importance of rapamycin as 
an activator of AMPK. In addition, treatment of TSC-
deficient  mice  with  rapamycin  showed  inhibition  of 
mTORC1 through increasing AMPK phosphorylation at 
Thr172 and it is downstream, ACC at Ser79 and accompanied 
by increased OGG1 activity [8]. Although lower 
concentrations of rapamycin appeared to inhibit mTOR 
activation in cancer cells, higher concentrations were 
required to increase the protein and promoter activity of 
OGG1, suggesting that high concentrations of rapamycin 
may be required to activates other kinases such as AMPK 
in addition to blocking mTOR activity [8]. In support of 
this hypothesis, rapamycin increases phosphorylation of 
AMPK, an upstream signaling intermediate in the mTOR 
pathway in different cancer cells. Moreover, rapamycin 
promotes AMPK activity as well as evidenced by 
increasing ACC phosphorylation. Activation of AMPK by 
rapamycin results in the inhibition of mTOR activity and 
increased the protein expression and promoter activity of 
OGG1 in proximal tubular cells. Moreover, activation of 
AMPK by AICAR resulted in inhibition of mTOR and 
increases the promoter activity and protein expression of 
OGG1 in tuberin-deficient and VHL-deficient cells [8]. 
Since AICAR increased the protein expression and the 
promoter activity of OGG1 in TSC2-null cells, it opens the 
possibility that induction of OGG1 by AMPK is through a 
pathway independent of TSC2. Thus AMPK may inhibits 
mTOR without activates of TSC2 and augment OGG1 
expression, or, AMPK may induce OGG1 expression 
through unknown mTOR-independent mechanism (Figure 
1). These data strongly suggest that rapamycin may acts 
as a direct activator of AMPK to phosphorylate raptor at 
Ser722/Ser792 and inhibit mTOR that lead to activate the 
DNA repair enzyme OGG1 in cancer cells.
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